Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-06931-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Jessica E Wijngaarden und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands. j.e.wijngaarden@amsterdamu…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Introduction
The novel positron emission tomography (PET) imaging tracer, [ 18 F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [ 18 F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.
Methods
Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input functions were analysed using single-tissue reversible (1T2k), two-tissue irreversible (2T3k) and two-tissue reversible (2T4k) plasma input models. Simplified uptake measures, such as standardised uptake value (SUV) and tumour-to-blood (TBR) or tumour-to-plasma ratio (TPR), were evaluated for different time intervals.
Results
Whole-blood and plasma radioactivity concentrations showed rapid clearance of [ 18 F]F-AraG. Metabolite analysis revealed a low rate of metabolism, at 70 min p.i., on average, 79% (SD = 9.8%) of the total radioactivity found in blood corresponded to intact [ 18 F]F-AraG. The time activity curves were best fitted by the 2T3k model. Strong positive correlations were found for SUV (body weight (BW), lean body mass (LBM) or body surface area (BSA) corrected), TBR and TPR for any time interval between 20 and 70 min p.i. against the 2T3k-derived K i . The correlation of TBR at 60–70 min p.i. with 2T3K-derived K i (r (df = 20) = 0.87, p < 0.01), was stronger than for SUV BW (r (df = 20) = 0.80, p < 0.01).
Conclusion
Tumour lesion [ 18 F]F-AraG uptake in patients with NSCLC is characterised by a 2T3k model. TBR and TPR show most potential for simplified quantification of tumour lesion [ 18 F]F-AraG uptake in patients with NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands. j.e.wijngaarden@amsterdamumc.nl.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. j.e.wijngaarden@amsterdamumc.nl.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Department of Pulmonary Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
ORCID-Profile: Jessica E Wijngaarden, Maarten Slebe
Förderung
- Boehringer Ingelheim
Zitieren
APA
Wijngaarden, J. E., Slebe, M., Pouw, J. E. E., Oprea-Lager, D. E., Schuit, R. C., Dickhoff, C., Levi, J., Windhorst, A. D., Oordt, C. W. M. H. V., Thiele, A., Bahce, I., Boellaard, R., & Yaqub, M. (2025). Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06931-3
Vancouver
Wijngaarden JE, Slebe M, Pouw JEE, Oprea-Lager DE, Schuit RC, Dickhoff C, et al. Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06931-3
BibTeX
@article{Wijngaarden2025,
author = {Wijngaarden, Jessica E and Slebe, Maarten and Pouw, Johanna E E and Oprea-Lager, Daniela E and Schuit, Robert C and Dickhoff, Chris and Levi, Jelena and Windhorst, Albert D and Oordt, C Willemien Menke-van der Houven van and Thiele, Andrea and Bahce, Idris and Boellaard, Ronald and Yaqub, Maqsood},
title = {Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-06931-3}
}
EUVIMED